Geisinger Commonwealth School of Medicine

Castle Biosciences to Present New Data on its TissueCypher® Barrett’s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting

Retrieved on: 
Tuesday, October 24, 2023
Research, Genetics, Biotechnology, Other Health, Health, General Health, Other Science, Science, Oncology, Patient, EAC, American College, IND, Identity, New York University Grossman School of Medicine, Medicare, Physician, ACG, Pathology, Cancer, BE, University School, Dysplasia, Geisinger Commonwealth School of Medicine, Risk, American College of Gastroenterology, LGD, HGD, Geisinger Medical Center, Diagnosis, Nursing, Medical imaging, Medicine

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher® test in patients with Barrett’s esophagus (BE) through two posters at the 2023 American College of Gastroenterology (ACG 2023) Annual Scientific Meeting, taking place Oct. 20-25, in Vancouver, Canada.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher® test in patients with Barrett’s esophagus (BE) through two posters at the 2023 American College of Gastroenterology (ACG 2023) Annual Scientific Meeting, taking place Oct. 20-25, in Vancouver, Canada.
  • “However, we find that at least half of the patients who progress to EAC come from this “low-risk” population, which tells us that there is a critical need to improve our risk-stratification of these patients.
  • In patients with higher-risk clinicopathologic factors (males with a pathology diagnosis of indefinite for dysplasia (IND) or LGD), TissueCypher identified low-risk patients with predicted progression rates similar to patients with NDBE.
  • Overall, the data show the risk stratification provided by the TissueCypher test can aid physicians and patients in making risk-aligned patient management decisions, such as escalated or de-escalated care, which may lead to improved health outcomes.

Rice Biotech Launch Pad expands external advisory board with Kevin Sheridan

Retrieved on: 
Tuesday, October 17, 2023
Neuroscience, Jefferies, MBA, Bill & Melinda Gates Foundation, Massachusetts Institute of Technology, CTMC, Faculty, Rice, Launch pad, Columbia Business School, Rutgers University, Goldman Sachs, Rice University, Biotechnology, Green Launching Pad, MD Anderson Cancer Center, Harris Health System, Argonne National Laboratory, College of Engineering (KNUST), Growth, Chemistry, Geisinger Commonwealth School of Medicine, ApiJect Systems, Research, Integration, UBS, Pharmaceutical industry, Management

HOUSTON, Oct. 17, 2023 /PRNewswire/ -- Rice University today announced the addition of Kevin Sheridan to its external advisory board for the Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures. 

Key Points: 
  • HOUSTON, Oct. 17, 2023 /PRNewswire/ -- Rice University today announced the addition of Kevin Sheridan to its external advisory board for the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.
  • "With the formation of the external advisory board earlier this month , the Rice Biotech Launch Pad is well-positioned to stand out among other accelerators and to have a meaningful impact on the biotech industry with the invaluable insights provided by the board," said Omid Veiseh , associate professor of bioengineering at Rice and faculty director of the accelerator.
  • "Kevin is the next piece of the puzzle to building out the phenomenal group of executives that comprise our external advisory board.
  • Sheridan is the 12th member of the Launch Pad's external advisory board.

The Inner Circle Acknowledges, Thomas P. Olenginski, MD, FACP as a Pinnacle Lifetime Member for his contributions to the field of Rheumatology

Retrieved on: 
Monday, October 16, 2023
Certification, United Methodist Church, Geisinger, Internal medicine, Fellow, International Society, Osteoporosis, School, American College, Bachelor of Science in Nursing, South Central Pennsylvania, Society, Arthritis Foundation, International Society for Clinical Densitometry, Fracture, Rheumatoid arthritis, Arthritis, Geisinger Commonwealth School of Medicine, FACP, Medical school, Pennsylvania State University, American College of Rheumatology, American College of Physicians, Relaxation, Athlete, Inner circle, Patient, Quality of life, Nursing, MD, Rheumatology, Medicine, Physician

LEWISBURG, Pa., Oct. 16, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Thomas P. Olenginski, MD, FACP is acknowledged as a Pinnacle Lifetime Member for his contributions to the field of Rheumatology.

Key Points: 
  • LEWISBURG, Pa., Oct. 16, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Thomas P. Olenginski, MD, FACP is acknowledged as a Pinnacle Lifetime Member for his contributions to the field of Rheumatology.
  • Dr. Olenginski pursued his pre-medical studies at Pennsylvania State University where he earned a Bachelor of Science degree.
  • The doctor has many roles at Geisinger Commonwealth School of Medicine, including teaching fellows in rheumatology and medical students with a focus on osteoporosis.
  • He actively participates in St. Paul's United Methodist Church, where he is a valued member, embodying his commitment to his faith and community involvement.

Rice Biotech Launch Pad introduces external advisory board

Retrieved on: 
Wednesday, October 4, 2023
Rice University, THOR, Neuroscience, Omid Veiseh, MBA, Geisinger Commonwealth School of Medicine, College of Engineering (KNUST), ARPA, Science, Harris Health System, Launch pad, Research, Health, Integration, Green Launching Pad, Massachusetts Institute of Technology, Pharmaceutical industry, Management

HOUSTON, Oct. 4, 2023 /PRNewswire/ -- Rice University today announced its external advisory board for the Rice Biotech Launch Pad, the new accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures. Officially unveiled in September, the accelerator will help Rice researchers to advance internally discovered platform technologies from concept to clinical studies and commercialization.

Key Points: 
  • Group includes national and Houston-based leaders in science, academia, venture capital and investment banking
    HOUSTON, Oct. 4, 2023 /PRNewswire/ -- Rice University today announced its external advisory board for the Rice Biotech Launch Pad , the new accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.
  • The external advisory board members are:
    Albert Cha, M.D., Ph.D., managing partner at Frazier Life Sciences , a health care investment firm.
  • I look forward to welcoming them to the Rice Biotech Launch Pad team as we continue to scale the capabilities of the accelerator."
  • We appreciate the commitment and dedication of the external advisory board members to help us realize the vision of the Biotech Launch Pad."

TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus

Retrieved on: 
Friday, September 8, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Male, Probability, LGD, Geisinger Medical Center, ISDE, Pathology, Cancer, Medicine, Geisinger Commonwealth School of Medicine, EAC, Congress, BE, HGD, Dysplasia, Physician, Risk, Diagnosis, IND, Pharmaceutical industry, Medical imaging, Patient

Most patients were male (61.8%), under surveillance in a community-based practice (94.9%) and had a diagnosis of non-dysplastic Barrett’s esophagus (NDBE) (95.1%), which is representative of the general BE patient population.

Key Points: 
  • Most patients were male (61.8%), under surveillance in a community-based practice (94.9%) and had a diagnosis of non-dysplastic Barrett’s esophagus (NDBE) (95.1%), which is representative of the general BE patient population.
  • Patients with NDBE are considered to be at low risk for progression based on their clinical risk factors.
  • These data demonstrate that TissueCypher provided impactful risk stratification, independent of clinicopathologic risk factors, to enable risk-aligned management of BE patients.
  • This included objective information to support surveillance-only management for patients with a low risk of progression and escalated surveillance/treatment for patients at high risk of progression.

Dr. David B. Nash Joins HealthTrackRx Strategic Advisory Board

Retrieved on: 
Tuesday, April 25, 2023
MedPage Today, Central Waqf Council, Population Health Management, Commission, Infection, JCPH, MBA, Commission on the Accreditation of Healthcare Management Education, COVID, Geisinger Commonwealth School of Medicine, Organization, American Journal, Publication, MD, Patient, Population health, Modern Healthcare, Healthcare in the United States, Humana, Accreditation, Jefferson College, Health, Book, PCR, American Journal of Medical Quality, Pharmaceutical industry, Nursing

DENTON, Texas, April 25, 2023 /PRNewswire/ -- HealthTrackRx, the nation's premier molecular diagnostic testing laboratory, today announced that David B. Nash, MD, MBA, the Founding Dean Emeritus at the Jefferson College of Population Health (JCPH), has joined its Strategic Advisory Board. A board-certified internist, Dr. Nash is internationally recognized for his work in public accountability for health outcomes, physician leadership development, and quality-of-care improvement.

Key Points: 
  • DENTON, Texas, April 25, 2023 /PRNewswire/ -- HealthTrackRx, the nation's premier molecular diagnostic testing laboratory, today announced that David B. Nash, MD, MBA, the Founding Dean Emeritus at the Jefferson College of Population Health (JCPH), has joined its Strategic Advisory Board.
  • A board-certified internist, Dr. Nash is internationally recognized for his work in public accountability for health outcomes, physician leadership development, and quality-of-care improvement.
  • "HealthTrackRx is transforming the way providers diagnose and treat infections," said Dr. Nash.
  • I am thrilled to join HealthTrackRx in developing clinical innovations that will get people healthier faster."

FNCB Bancorp, Inc. Mourns the Passing of Board Member John P. Moses, Esquire

Retrieved on: 
Tuesday, November 22, 2022
Growth, Supreme, Blue Cross Blue Shield Association, Hospital, Villanova University School of Law, Lead, Law, Bank, Cheating, Professional Football Compensation Committee, Small business, Housing, Communities and Local Government Committee, Christian Brothers University, Geisinger Commonwealth School of Medicine, Ellis Island Medal of Honor, Private practice, Dunmore, Supreme court, ALSAC, Management, Medicine, Counsel

DUNMORE, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- FNCB Bancorp, Inc. (NASDAQ: FNCB; www.fncb.com ), the parent company of Dunmore-based FNCB Bank (Bank), has announced that John P. Moses, Esquire, a member of the Board of Directors, passed away on October 31, 2022.

Key Points: 
  • DUNMORE, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- FNCB Bancorp, Inc. (NASDAQ: FNCB; www.fncb.com ), the parent company of Dunmore-based FNCB Bank (Bank), has announced that John P. Moses, Esquire, a member of the Board of Directors, passed away on October 31, 2022.
  • John was the Lead Director of FNCB Bancorp, Inc. and FNCB Bank and served as a member of the Companys Audit and Compensation Committees and was Chairman of the Nominating and Governance Committee.
  • Johns leadership since joining the board of directors in 1999 was instrumental in FNCB's growth and success.
  • John was not only an excellent ambassador for FNCB but a good friend as well and will be deeply missed, said Gerard Champi, FNCB Bank President and CEO.

Geisinger's northeast hospitals certified as Comprehensive Heart Attack Centers

Retrieved on: 
Thursday, September 15, 2022
Geisinger Commonwealth School of Medicine, Certification, Time, Safety, Oxygen, Chest pain, Twitter, Nursing, Emergency medical services, Joint, Muscle tissue, Joint Commission, LinkedIn, Geisinger Medical Center, Heart failure, GMC, Patient, Emergency medicine, Physician, Instagram, Quality of life, Pharmacist, Geisinger, Sarah Cannon Research Institute, GCMC, AHA, EMS, Record, Heart, Pain management, Pharmacy, Hospital, Education, Medical device, Accreditation, Facebook

WlLKES-BARRE, Pa. and SCRANTON, Pa., Sept. 15, 2022 /PRNewswire/ -- Geisinger Wyoming Valley Medical Center (GWV) and Geisinger Community Medical Center (GCMC) recently became the second and third hospitals in the country to earn The Joint Commission/American Heart Association (AHA) Comprehensive Heart Attack Center Certification, joining Geisinger Medical Center (GMC) in Danville in establishing a national precedent for coordination among care teams who treat patients on the heart attack spectrum.

Key Points: 
  • A heart attack occurs when blood flow to the heart is blocked, depriving the heart of oxygen.
  • Much of the damage to heart muscle takes place in a short period of time after a heart attack, so timely care is critical for preserving heart function.
  • "No one expects to have a heart attack, but when it happens, we offer extraordinary care close to home for our patients and members," said Yassir Nawaz, M.D., director of interventional cardiology and co-medical director of the Comprehensive Heart Attack Center Certification program for Geisinger's northeast region.
  • "With three certified medical centers, we're taking a full-team approach to diagnosing and treating chest pain patients in northeastern and central Pennsylvania."

Dr. Susan Parisi named Geisinger's first chief wellness officer

Retrieved on: 
Thursday, July 28, 2022
Well, Geisinger Commonwealth School of Medicine, University, Occupational burnout, View, Alternative, Center, American College, Physician, Gynaecology, Twitter, Instagram, Decision-making, Hospital, Culture, Professional, Genetics, Health, Stanford University, COVID-19, Multimedia, Obstetrics, Organization, Gibbs Cancer Center & Research Institute, Mental health, Workplace, Patient, LinkedIn, Post-traumatic stress disorder, Depression, New York Medical College, Cornell University, American College of Obstetricians and Gynecologists, Geisinger, Anxiety, Pharmaceutical industry, Medicine, Facebook, Science

DANVILLE, Pa., July 28, 2022 /PRNewswire/ -- Furthering Geisinger's commitment to investing in the health and well-being of its employees, Susan Parisi, M.D., has been named the health system's first chief wellness officer.

Key Points: 
  • DANVILLE, Pa., July 28, 2022 /PRNewswire/ -- Furthering Geisinger's commitment to investing in the health and well-being of its employees, Susan Parisi, M.D., has been named the health system's first chief wellness officer.
  • She'll also oversee advocacy programs and initiatives aimed at enhancing shared decision making, professional satisfaction, autonomy and a culture of professionalism and respect.
  • "Our employees are the heart of everything we do," said Janet Tomcavage, Geisinger executive vice president and chief nursing officer.
  • After supporting fellow physicians through their own experiences with burnout and emotional exhaustion, Dr. Parisi pursued the prestigious Stanford Chief Wellness Officer training, which she completed in 2019.

Geisinger and Cohere Health Join in Driving High-Value Care and Reducing Provider Burden

Retrieved on: 
Tuesday, July 12, 2022
Technology, GHP, Geisinger Commonwealth School of Medicine, Health, Commercial, LinkedIn, Medicare Advantage, J.D. Power, Digital, Medicaid, Patient, Friction, CEO, CB Insights, MD, Instagram, Physician, Population, Geisinger Health System, Medicare, Commercial Exchange Building (Jackson, Michigan), Research, Twitter, Polaris Partners, Industry, Health insurance, Medicine, Medical device, Geisinger, Intracoronary optical coherence tomography, Facebook

DANVILLE, Pa. and BOSTON, July 12, 2022 /PRNewswire/ -- Today Geisinger Health Plan (GHP) and Cohere Health, a recognized leader in utilization management (UM) technology, announced they are joining forces to drive high-value care and reduce provider burden. Cohere's collaborative UM platform will help GHP support value-based care delivery, reduce administrative costs, and lead the nation in aligning quality improvement initiatives across all its lines of business, including Commercial, Exchange, Medicare Advantage, and the newly expanded Medicaid.

Key Points: 
  • DANVILLE, Pa. and BOSTON, July 12, 2022 /PRNewswire/ --Today Geisinger Health Plan (GHP) and Cohere Health, a recognized leader in utilization management (UM) technology, announced they are joining forces to drive high-value care and reduce provider burden.
  • "Working with Cohere Health is a transformational step in Geisinger's long history of clinical innovation, both in Pennsylvania and nationwide," said John Bulger, MD, chief medical officer for Geisinger Health Plan.
  • "We're thrilled to work with Geisinger Health Plan on a digital-first approach to transforming utilization management that furthers their mission: providing members with high-quality, affordable care," said Siva Namasivayam, CEO of Cohere Health.
  • Cohere Health is a digital intelligence company that's transforming utilization management (UM) by aligning physicians and health plans on evidence-based care paths for the patient's entire care journey.